Integrated Filing — IndAS

General information about company
Scrip Code	543245
NSE Symbol	GLAND
MSEI Symbol	NOTLISTED
ISIN	INE068V01023
Name of company	GLAND PHARMA LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	20-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	06-May-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Pharmaceuticals
Start date and time of board meeting	20-May-2025   15:00:00
End date and time of board meeting	20-May-2025   16:15:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	2025-05-20
Indicate Company website link for updated RPT policy of the Company	https://glandpharma.com/images/Policy_of_Related_Party_Transactions.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
Not applicable for the quarter

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	10303530000	41161490000
	Other income	437180000	2150750000
	Total income	10740710000	43312240000
2	Expenses
(a)	Cost of materials consumed	4693920000	15858570000
(b)	Purchases of stock-in-trade	30990000	144880000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-672780000	1302490000
(d)	Employee benefit expense	1196950000	4390230000
(e)	Finance costs	34460000	228370000
(f)	Depreciation, depletion and amortisation expense	430720000	1692710000
(f)	Other Expenses
1	Power and fuel	286270000	1203820000
2	Other expenses	826950000	3835320000
	Total other expenses	1113220000	5039140000
	Total expenses	6827480000	28656390000
3	Total profit before exceptional items and tax	3913230000	14655850000
4	Exceptional items	0	0
5	Total profit before tax	3913230000	14655850000
6	Tax expense
7	Current tax	990720000	3667080000
8	Deferred tax	22520000	91240000
9	Total tax expenses	1013240000	3758320000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	2899990000	10897530000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	2899990000	10897530000
17	Other comprehensive income net of taxes	-45920000	-29250000
18	Total Comprehensive Income for the period	2854070000	10868280000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	164760000	164760000
	Face value of equity share capital	1	1
27	Details of debt securities
22	Reserves excluding revaluation reserve		97386260000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	17.6	66.15
	Diluted earnings (loss) per share from continuing operations	17.6	66.15
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	17.6	66.15
	Diluted earnings (loss) per share from continuing and discontinued operations	17.6	66.15
24	Debt equity ratio
25	Debt service coverage ratio
26	Interest service coverage ratio
27	Disclosure of notes on financial results		1In terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015 as amended the Listing requirements this Statement of Standalone Financial Results for the quarter and year ended March 31 2025 Standalone Financial Results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 20 2025The statutory auditors of the Company have expressed an unmodified opinion on the financial results for the year ended March 31 2025 and have issued an unmodified conclusion on the financial results for the quarter ended March 31 20252The Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013 as amended and read with relevant rules thereunder and in terms of the Listing requirements3The figures of the fourth quarter are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures up to the end of the third quarter of the relevant financial year which were subjected to a limited reviewRefer the signed results uploaded for the complete notes

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets
1	Non-current assets
	Property, plant and equipment	17358570000
	Capital work-in-progress	422050000
	Investment property	0
	Goodwill	0
	Other intangible assets	64580000
	Intangible assets under development	0
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets
	Non-current investments	27895670000
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets	0
	Total non-current financial assets	27895670000
	Deferred tax assets (net)	0
	Other non-current assets	805680000
	Total non-current assets	46546550000
2	Current assets
	Inventories	12542330000
	Current financial asset
	Current investments	0
	Trade receivables, current	11428990000
	Cash and cash equivalents	24326220000
	Bank balance other than cash and cash equivalents	0
	Loans, current	0
	Other current financial assets	4935310000
	Total current financial assets	40690520000
	Current tax assets (net)	0
	Other current assets	4436790000
	Total current assets	57669640000
3	Non-current assets classified as held for sale	0
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	104216190000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	164760000
	Other equity	97386260000
	Total equity attributable to owners of parent	97551020000
	Non controlling interest
	Total equity	97551020000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	11090000
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	0
	Other non-current financial liabilities	24050000
	Total non-current financial liabilities	35140000
	Provisions, non-current	228370000
	Deferred tax liabilities (net)	1164010000
	Deferred government grants, Non-current	0
	Other non-current liabilities	0
	Total non-current liabilities	1427520000
	Current liabilities
	Current financial liabilities
	Borrowings, current	14420000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	63010000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	3795650000
	Total Trade payable	3858660000
	Other current financial liabilities	207540000
	Total current financial liabilities	4080620000
	Other current liabilities	658330000
	Provisions, current	57230000
	Current tax liabilities (Net)	441470000
	Deferred government grants, Current	0
	Total current liabilities	5237650000
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	Total liabilities	6665170000
	Total equity and liabilites	104216190000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Unaudited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Remeasurement of defined benefit plans	-61370000	-39090000
	Total Amount of items that will not be reclassified to profit and loss	-61370000	-39090000
2	Income tax relating to items that will not be reclassified to profit or loss	-15450000	-9840000
3	Amount of items that will be reclassified to profit and loss
	Total Amount of items that will be reclassified to profit and loss
4	Income tax relating to items that will be reclassified to profit or loss	0	0
5	Total Other comprehensive income	-45920000	-29250000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Unaudited
D	Nature of report standalone or consolidated			Standalone
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			14655850000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			228370000
	Adjustments for decrease (increase) in inventories			59740000
	Adjustments for decrease (increase) in trade receivables, current			220840000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			-1493900000
	Adjustments for decrease (increase) in other non-current assets			0
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			0
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			1075450000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			-208040000
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			1692710000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			0
	Adjustments for provisions, current			0
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			0
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			5720000
	Adjustments for dividend income			0
	Adjustments for interest income			0
	Adjustments for share-based payments			0
	Adjustments for fair value losses (gains)			0
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			-2004260000
	Other adjustments to reconcile profit (loss)			0
	Other adjustments for non-cash items			25950000
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			-397420000
	Net cash flows from (used in) operations			14258430000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			3521700000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			10736730000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			4038320000
	Other cash receipts from sales of equity or debt instruments of other entities			0
	Other cash payments to acquire equity or debt instruments of other entities			0
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			237260000
	Purchase of property, plant and equipment			1351090000
	Proceeds from sales of investment property			0
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			0
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			0
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			1513420000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			19420710000
	Net cash flows from (used in) investing activities	15781980000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			0
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			24880000
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			0
	Repayments of borrowings			7100000
	Payments of lease liabilities			4020000
	Dividends paid			3294880000
	Interest paid			114320000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			-3395440000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			23123270000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			40900000
	Net increase (decrease) in cash and cash equivalents			23164170000
	Cash and cash equivalents cash flow statement at beginning of period			1162050000
	Cash and cash equivalents cash flow statement at end of period			24326220000